Smith & Nephew (LON:SN) Receives Overweight Rating from JPMorgan Chase & Co.

JPMorgan Chase & Co. restated their overweight rating on shares of Smith & Nephew (LON:SN) in a research report sent to investors on Thursday, MarketBeat.com reports. JPMorgan Chase & Co. currently has a GBX 1,300 ($16.18) target price on the stock.

A number of other research analysts have also recently issued reports on SN. Barclays reissued an equal weight rating and set a GBX 1,150 ($14.32) price objective on shares of Smith & Nephew in a report on Friday, February 9th. Royal Bank of Canada reaffirmed an outperform rating and issued a GBX 1,500 ($18.67) price target on shares of Smith & Nephew in a report on Friday, April 5th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of Moderate Buy and an average target price of GBX 1,362.50 ($16.96).

Smith & Nephew Stock Up 0.7 %

Shares of SN stock opened at GBX 966.80 ($12.04) on Thursday. The stock has a market cap of £8.45 billion, a P/E ratio of 4,000.83, a price-to-earnings-growth ratio of 0.46 and a beta of 0.51. Smith & Nephew has a one year low of GBX 887 ($11.04) and a one year high of GBX 1,316.75 ($16.39). The stock has a fifty day moving average price of GBX 1,048.36 and a 200 day moving average price of GBX 1,034.10. The company has a debt-to-equity ratio of 59.11, a current ratio of 1.77 and a quick ratio of 0.84.

Smith & Nephew Increases Dividend

The company also recently disclosed a dividend, which will be paid on Wednesday, May 22nd. Investors of record on Thursday, March 28th will be given a $0.23 dividend. This represents a yield of 1.62%. This is a positive change from Smith & Nephew’s previous dividend of $0.14. The ex-dividend date of this dividend is Thursday, March 28th. Smith & Nephew’s dividend payout ratio (DPR) is presently 12,500.00%.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.